Heart Failure with Preserved Ejection Fraction (HFpEF) Clinical Trials

• Age 40-84 years (both inclusive) at the time of signing the informed consent

• Documented symptomatic chronic heart failure (HF) diagnosed greater than or equal to (≥) 90 days prior to screening with at least weekly need for oral diuretic treatment, and New York Heart Association class II-III at screening

• Clinically stable and on optimised doses and unchanged drug classes of guideline-directed HF therapy ≥45 days prior to randomisation

• Left ventricular ejection fraction ≥50% as assessed by echocardiography at screening, measured by central laboratory

• Left ventricular hypertrophy assessed by echocardiography at screening measured by central laboratory with any of the following:

‣ LVMi (greater than) \>88 gram per square meter (g/m\^2) for female participants and \>102 g/m\^2 for male participants, using the truncated ellipsoid method measured by central laboratory

⁃ LVMi \>95 g/m2 for female participants and \>115 g/m2 for male participants using the linear method (cube formula).

⁃ Interventricular septum diameter measured in diastole (IVSd) in the parasternal long axis view ≥1.1 cm for female participants and ≥1.2 cm for male participants.

• Body mass index 18.5-40 kilogram per square meter (kg/m\^2) (both inclusive) and body weight less than or equal to (≤) 140 kilogram (kg). Body mass index is calculated in the electronic case report form based on height and body weight at the screening visit (visit 1)

• NT-proBNP ≥300 picograms per milliliter (pg/mL); NT-proBNP ≥600 pg/mL if atrial fibrillation/flutter is present at time of screening, measured by central laboratory